Related Experiment Video
Updated: May 26, 2026
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
Cardioprotective effects of gallic acid in diabetes-induced myocardial dysfunction in rats
Snehal S Patel1, Ramesh K Goyal
1Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad 382 481, India.
Background:
Normalization of hyperglycemia, hyperlipidemia, and oxidative stress is an important objective in preventing diabetes-induced cardiac dysfunction.
Objective:
This study was undertaken to examine the effects of gallic acid in myocardial dysfunctions associated with type-1 diabetes.
Materials And Methods:
Diabetes was induced by single intravenous injection of streptozotocin (STZ, 50 mg/kg i.v.). Gallic acid was administered daily at three different doses (100, 50, and 25 mg/kg p.o.) for 8 weeks at the end of which blood samples were collected and analyzed for various biochemical parameters.
Results:
Injection of STZ produced significant loss of body weight (BW), polyphagia, polydypsia, hyperglycemia, hypoinsulinemia, hyperlipidemia, hypertension, bradycardia, and myocardial functional alterations. Treatment with gallic acid significantly lowered fasting glucose, the AUC(glucose) level in a dose-dependent manner; however, the insulin level was not increased significantly at same the dose and prevented loss of BW, polyphagia, and polydypsia in diabetic rats. It also prevented STZ-induced hyperlipidemia, hypertension, bradycardia, structural alterations in cardiac tissue such as increase in force of contraction, left ventricular weight to body weight ratio, collagen content, protein content, serum lactate dehydrogenase, and creatinine kinase levels in a dose-dependent manner. Further, treatment also produced reduction in lipid peroxidation and increase in antioxidant parameters in heart of diabetic rats.
Conclusion:
The results of this study suggest that gallic acid to be beneficial for the treatment of myocardial damage associated with type-1 diabetes.
Insights
Gallic acid treatment improved cardiac function in type-1 diabetes by reducing hyperglycemia, hyperlipidemia, and oxidative stress. This suggests gallic acid is beneficial for treating diabetes-related myocardial damage.
Area of Science:
- Cardiovascular Research
- Diabetology
- Pharmacology
Background:
- Diabetes mellitus, particularly type-1, is associated with significant cardiac dysfunction.
- Hyperglycemia, hyperlipidemia, and oxidative stress are key contributors to diabetes-induced myocardial damage.
- Effective interventions are crucial for preventing and treating diabetic cardiomyopathy.
Purpose of the Study:
- To investigate the cardioprotective effects of gallic acid in a type-1 diabetes model.
- To evaluate gallic acid's impact on biochemical and functional parameters of the diabetic heart.
Main Methods:
- Type-1 diabetes was induced in rats using streptozotocin (STZ).
- Rats were treated with varying doses of gallic acid (25, 50, 100 mg/kg) for 8 weeks.
- Biochemical markers, cardiac function, and tissue structure were assessed.
Main Results:
- STZ-induced diabetes caused hyperglycemia, hyperlipidemia, hypertension, bradycardia, and cardiac structural changes.
- Gallic acid treatment dose-dependently improved glycemic control, reduced hyperlipidemia and hypertension, and normalized heart rate.
- Gallic acid mitigated cardiac structural damage, reduced lipid peroxidation, and enhanced antioxidant status in diabetic hearts.
Conclusions:
- Gallic acid demonstrates significant cardioprotective effects in type-1 diabetes.
- The findings support gallic acid as a potential therapeutic agent for diabetic cardiomyopathy.
- Further research into gallic acid's mechanisms in diabetes is warranted.
